Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
Launched by BOEHRINGER INGELHEIM · Feb 18, 2009
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patients of 18 years of age or above undergoing elective total hip or knee replacement surgery who consent in writing to their participation in this observational study
- Exclusion criteria:
- • All patients who should not be treated with Pradaxa 220 mg according to the European Summary of Product Characteristics (SPC): age of \> 75 years, renal impairment (creatinine clearance \<50 ml/min), patients with concomitant therapy of amiodarone, elevated liver enzymes \> 2 upper limit of normal (ULN) and/or hepatic impairment or liver disease expected to have any impact on survival, anaesthesia with post operative indwelling epidural catheters, hypersensitivity to dabigatran etexilate or to any of the excipients, active clinically significant bleeding, organic lesion at risk of bleeding, spontaneous or pharmacological impairment of haemostasis except for the above included patients groups, concomitant treatment with quinidine
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
Klagenfurt, , Austria
Linz, , Austria
Linz, , Austria
St. Johann/Tirol, , Austria
Stolzalpe, , Austria
Wels, , Austria
Wien, , Austria
Wien, , Austria
Wien, , Austria
Wien, , Austria
Angers, , France
Bois Guillaume Cédex, , France
Bordeaux, , France
Caen Cedex 9, , France
Clermont Ferrand Cedex 1, , France
Creteil, , France
Dijon Cédex, , France
Illkirch, , France
Le Havre, , France
Les Lilas, , France
Lille Cedex, , France
Lyon, , France
Marseille, , France
Metz, , France
Nantes Cédex 2, , France
Paris Cedex 10, , France
Paris Cedex 14, , France
Paris, , France
Paris, , France
Pierre Bénite Cedex, , France
Poitiers Cédex, , France
Saint Etienne Cédex 2, , France
Saint Saulve, , France
Toulouse Cedex 9, , France
Toulouse Cédex 9, , France
Vannes Cédex, , France
Bad Homburg, , Germany
Bayreuth, , Germany
Berlin, , Germany
Bochum, , Germany
Breitenbrunn, , Germany
Chemnitz, , Germany
Erlangen, , Germany
Fürth, , Germany
Garmische Partenkirchen, , Germany
Gelnhausen, , Germany
Gelsenkirchen, , Germany
Günzburg, , Germany
Hachenburg, , Germany
Hamburg, , Germany
Hannover, , Germany
Hof, , Germany
Kamp Linfort, , Germany
Kassel, , Germany
Koblenz, , Germany
Landstuhl, , Germany
Lübben, , Germany
Mainz, , Germany
Marburg, , Germany
Markgröningen, , Germany
Marktheidenfeld, , Germany
Merseburg, , Germany
Minden, , Germany
München, , Germany
München, , Germany
Nürnberg, , Germany
Olsberg, , Germany
Pfortzheim, , Germany
Rosenheim, , Germany
Rostock, , Germany
Rostock, , Germany
Rotenburg/Fulda, , Germany
Schwarzenbruck, , Germany
Sylt, , Germany
Wertheim, , Germany
Wiesbaden, , Germany
Wismar, , Germany
Worms, , Germany
Würzburg, , Germany
Würzburg, , Germany
Croom, , Ireland
Bari, , Italy
Firenze, , Italy
Genova, , Italy
Jesi (An), , Italy
Latina, , Italy
Mantova, , Italy
Ome (Bs), , Italy
Roma, , Italy
Torino, , Italy
Vimercate (Mi), , Italy
Koscierzyna, , Poland
Lodz, , Poland
Otwock, , Poland
Piekary Slaskie, , Poland
Swiebodzin, , Poland
Madrid, , Spain
Madrid, , Spain
Malaga, , Spain
Pamplona, , Spain
Valencia, , Spain
Zaragoza, , Spain
Kungälv, , Sweden
Motala, , Sweden
Solleftea, , Sweden
Basildon, , United Kingdom
Gateshead, , United Kingdom
Halifax, , United Kingdom
London, , United Kingdom
Luton, , United Kingdom
Wigan, , United Kingdom
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials